alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7421 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7421

  To amend Public Law 87-788 (commonly known as the McIntire-Stennis 
   Cooperative Forestry Act; 16 U.S.C. 582a-7) to provide for equal 
   treatment of the District of Columbia with respect to funds made 
                       available under that Act.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 20, 2024

  Ms. Norton introduced the following bill; which was referred to the 
                        Committee on Agriculture

_______________________________________________________________________

                                 A BILL

 
  To amend Public Law 87-788 (commonly known as the McIntire-Stennis 
   Cooperative Forestry Act; 16 U.S.C. 582a-7) to provide for equal 
   treatment of the District of Columbia with respect to funds made 
                       available under that Act.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``McIntire-Stennis Act District of 
Columbia Equality Act''.

SEC. 2. INCLUSION OF DISTRICT OF COLUMBIA FOR PURPOSES OF FUNDING UNDER 
              MCINTIRE-STENNIS COOPERATIVE FORESTRY ACT.

    Section 8 of Public Law 87-788 (commonly known as the McIntire-
Stennis Cooperative Forestry Act; 16 U.S.C. 582a-7) is amended by 
inserting ``the District of Columbia,'' after ``include''.
                                 <all>
```
§ 520.301 Caramiphen ethanedisulfonate and ammonium chloride tablets. ( a ) *Specifications.* Each tablet contains 10 milligrams of 5st caramiphen ethanedisulfonate and 80 milligrams of ammonium chloride.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* One tablet per 15 to 30 pounds of body weight every 4 to 6 hours.
( 2 ) *Indications for use.* For relief of cough.
[43 FR 55385, Nov. 28, 1978, as amended at 79 FR 28819, May 20, 2014. Redesignated at 80 FR 13229, Mar. 13, 2015]
<PAGE>   1
                                                                    EXHIBIT 10.2


              FIRST AMENDMENT TO THE NEXTLINK COMMUNICATIONS, INC.
                                STOCK OPTION PLAN


         The NEXTLINK COMMUNICATIONS, INC. Stock Option Plan is hereby amended,
effective September 1, 1997, to revise the last sentence of Subsection 5.2.1. to
read in its entirety as follows:

                  "With respect to nonqualified stock options, the exercise
         price shall be the amount set by the Plan Administrator."

         In all other respects, the NEXTLINK COMMUNICATIONS, INC. Stock Option
Plan shall remain the same.

                                       NEXTLINK COMMUNICATIONS, INC.


                                       By: /s/ R. BRUCE EASTER, JR.
                                          --------------------------------------
                                       Name:   R. Bruce Easter, Jr.
                                       Title:  Vice President and Secretary
Editorial Note on Part 170
Editorial Note: Nomenclature changes to part 170 appear at 66 FR 56035, Nov. 6, 2001, and 69 FR 13717, Mar. 24, 2004.

§ 170.101 Information in a premarket notification for a food contact substance (FCN). An FCN must contain the following: ( a ) A comprehensive discussion of the basis for the manufacturer's or supplier's determination that the use of the food contact substance is safe. This discussion must: ( 1 ) Discuss all information and data submitted in the notification; and
( 2 ) Address any information and data that may appear to be inconsistent with the determination that the proposed use of the food contact substance is safe.
( b ) All data and other information that form the basis of the determination that the food contact substance is safe under the intended conditions of use. Data must include primary biological data and chemical data.
( c ) A good laboratory practice statement for each nonclinical laboratory study, as defined under § 58.3(d) of this chapter, that is submitted as part of the FCN, in the form of either: ( 1 ) A signed statement that the study was conducted in compliance with the good laboratory practice regulations under part 58 of this chapter; or
( 2 ) A brief signed statement listing the reason(s) that the study was not conducted in compliance with part 58 of this chapter.
( 3 ) Data from any study conducted after 1978 but not conducted in compliance with part 58 of this chapter must be validated by an independent third party prior to submission to the Food and Drug Administration (FDA), and the report and signed certification of the validating party must be submitted as part of the notification.
( d ) Information to address FDA's responsibility under the National Environmental Policy Act, in the form of either: ( 1 ) A claim of categorical exclusion under § 25.30 or § 25.32 of this chapter; or
( 2 ) An environmental assessment complying with § 25.40 of this chapter.
( e ) A completed and signed FDA Form No. 3480.
EXHIBIT 32



CERTIFICATION PURSUANT TO

18
U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



In connection with the Annual Report on Form 10-K/A of SportsLine.com, Inc. (the Company) for the year ended December 31, 2003, as filed with the Securities and Exchange Commission on the date hereof (the
Report), we, Michael Levy and Sharon M. Glickman, Chief Executive Officer and Chief Financial Officer, respectively, of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act
of 2002, that to our knowledge:



|(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|--- | ---------------------------------------------------------------------------------------------------------------------



|(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------



|                                          
|------------------------------------------
|Dated November 8, 2004                    
|                                          
|/S/    MICHAEL
LEVY                       
|Michael Levy Chief Executive Officer      
|                                          
|/S/    SHARON M.
GLICKMAN                 
|Sharon M. Glickman Chief Financial Officer



A signed original of this written
statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to
SportsLine.com, Inc. and will be retained by SportsLine.com, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7333 Referred in Senate (RFS)]

<DOC>
118th CONGRESS
  2d Session
                                H. R. 7333

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             July 23, 2024

Received; read twice and referred to the Committee on Veterans' Affairs

_______________________________________________________________________

                                 AN ACT

 
To name the Department of Veterans Affairs medical center in West Palm 
     Beach, Florida, as the ``Thomas H. Corey VA Medical Center''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. NAME OF DEPARTMENT OF VETERANS AFFAIRS MEDICAL CENTER, WEST 
              PALM BEACH, FLORIDA.

     The Department of Veterans Affairs medical center in West Palm 
Beach, Florida, shall after the date of the enactment of this Act be 
known and designated as the ``Thomas H. Corey VA Medical Center''. Any 
reference to such medical center in any law, regulation, map, document, 
record, or other paper of the United States shall be considered to be a 
reference to the Thomas H. Corey VA Medical Center.

            Passed the House of Representatives July 22, 2024.

            Attest:

                                             KEVIN F. MCCUMBER,

                                                                 Clerk.
```
§ 1271.250 Labeling controls. ( a ) *General.* You must establish and maintain procedures to control the labeling of HCT/Ps. You must design these procedures to ensure proper HCT/P identification and to prevent mix-ups.
( b ) *Verification.* Procedures must include verification of label accuracy, legibility, and integrity.
( c ) *Labeling requirements.* Procedures must ensure that each HCT/P is labeled in accordance with all applicable labeling requirements, including those in §§ 1271.55, 1271.60, 1271.65, 1271.90, 1271.290, and 1271.370, and that each HCT/P made available for distribution is accompanied by documentation of the donor eligibility determination as required under § 1271.55.
-84 -82 -80 -78 -76 -74

 36

 38

 40

 42

▲ ★ ▲ ▲ ▲

★

▲

▲

▲

▲

 500

 1000

 1500

 500

18 12 06 00

06/21

NOAA HYSPLIT MODEL

 Backward trajectory ending at 2300 UTC 21 Jun 06

 EDAS Meteorological Data

Source

★ at 38.92 N 77.01 W Meters AGL
**Exhibit 21.1**

 

**Subsidiaries**

 
| **Name**                                | ** ** | **Jurisdiction of Organization** | ** ** |
|-----------------------------------------|------------|--------------------------------------------|------------|
| ** **                              | ** ** | ** **                                 | ** ** |
| Lifeboat   Distribution, Inc.      |       | Delaware                                   |       |
|                                    |       |                                       |       |
| Programmer’s   Paradise, Inc. |       | Delaware                                   |       |
|                                    |       |                                       |       |
| Programmers Paradise                    |       | Canada                                     |       |
|                                    |       |                                       |       |
| TechXtend, Inc.                    |       | Delaware                                   |       |
|                                    |       |                                       |       |
| Lifeboat Distribution,   Europe         |       | Netherlands                                |       |

 

----
#### § 225.180 Labeling.

Labels shall be received, handled, and stored in a manner that prevents label mixups and assures that the correct labels are used for the medicated feed. All deliveries of medicated feeds, whether bagged or in bulk, shall be adequately labeled to assure that the feed can be properly used.

[51 FR 7390, Mar. 3, 1986]
**Exhibit 32.2****CERTIFICATE PURSUANT TO****18 U.S.C. SECTION 1350,****AS ADOPTED PURSUANT TO****SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**     In connection with the Annual Report of Independence CommunityBank Corp. (the “Company”) on Form 10-K for theperiod ending December 31, 2005 as filed with theSecurities and Exchange Commission on the date hereof (the“Report”), I, Frank W. Baier, Executive VicePresident, Chief Financial Officer, Treasurer and PrincipalAccounting Officer of the Company, certify, pursuant to18 U.S.C. Section 1350, as adopted pursuant toSection 906 of the Sarbanes-Oxley Act of 2002, that:          (1) The Report fully complies with the requirements of    Section 13(a) or 15(d) of the Securities Exchange    Act of 1934; and           (2) The information contained in the Report fairly    presents, in all material respects, the financial condition and    results of operations of the Company.     /s/ Frank W. Baier           Frank W. Baier *Executive Vice President,* *Chief Financial Officer,* *Treasurer and Principal Accounting Officer*March 15, 2006     A signed original of this written statement required bySection 906 of theSarbanes-Oxley Act hasbeen provided to Independence Community Bank Corp. and will beretained by Independence Community Bank Corp. and furnished tothe Securities and Exchange Commission or its staff upon request.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THREE MONTHS
AND SIX MONTHS ENDED SEPTEMBER 30, 1998 AND 1997 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH 10-QSB.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          MAR-31-1998
<PERIOD-START>                             JUL-01-1997
<PERIOD-END>                               SEP-30-1998
<CASH>                                       1,716,690
<SECURITIES>                                         0
<RECEIVABLES>                                   55,600
<ALLOWANCES>                                     3,102
<INVENTORY>                                          0
<CURRENT-ASSETS>                             1,772,757
<PP&E>                                         182,908
<DEPRECIATION>                                 132,974
<TOTAL-ASSETS>                               2,006,169
<CURRENT-LIABILITIES>                          157,674
<BONDS>                                         11,845
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         4,833
<OTHER-SE>                                   1,831,767
<TOTAL-LIABILITY-AND-EQUITY>                 2,006,169
<SALES>                                              0
<TOTAL-REVENUES>                               138,836
<CGS>                                                0
<TOTAL-COSTS>                                   17,002
<OTHER-EXPENSES>                               270,857
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 525
<INCOME-PRETAX>                              (149,548)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (149,548)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (149,548)
<EPS-PRIMARY>                                    (.03)
<EPS-DILUTED>                                    (.03)
        

</TABLE>
Editorial Note on Part 509
Editorial Note: Nomenclature changes to part appear at 88 FR 45066, July 14, 2023.

§ 509.30 Temporary tolerances for polychlorinated biphenyls (PCB's). ( a ) Polychlorinated biphenyls (PCB's) are toxic, industrial chemicals. Because of their widespread, uncontrolled industrial applications, PCB's have become a persistent and ubiquitous contaminant in the environment. As a result, certain foods and animal feeds, principally those of animal and marine origin, contain PCB's as unavoidable, environmental contaminants. PCB's are transmitted to the food portion (meat, milk, and eggs) of food producing animals ingesting PCB contaminated animal feed. In addition, a significant percentage of paper food-packaging materials contain PCB's which may migrate to the packaged food. The source of PCB's in paper food-packaging materials is primarily of certain types of carbonless copy paper (containing 3 to 5 percent PCB's) in waste paper stocks used for manufacturing recycled paper. Therefore, temporary tolerances for residues of PCB's as unavoidable environmental or industrial contaminants are established for a sufficient period of time following the effective date of this paragraph to permit the elimination of such contaminants at the earliest practicable time. For the purposes of this paragraph, the term *polychlorinated biphenyls (PCB's)* is applicable to mixtures of chlorinated biphenyl compounds, irrespective of which mixture of PCB's is present as the residue. The temporary tolerances for residues of PCB's are as follows: ( 1 ) 0.2 part per million in finished animal feed for food-producing animals (except the following finished animal feeds: feed concentrates, feed supplements, and feed premixes).
( 2 ) 2 parts per million in animal feed components of animal origin, including fishmeal and other by-products of marine origin and in finished animal feed concentrates, supplements, and premixes intended for food-producing animals.
( 3 ) 10 parts per million in paper food-packaging material intended for or used with finished animal feed and any components intended for animal feeds. The tolerance shall not apply to paper food-packaging material separated from the food therein by a functional barrier which is impermeable to migration of PCB's.
( b ) A compilation entitled “Analytical Methodology for Polychlorinated Biphenyls, February 1973” for determining compliance with the tolerances established in this section is available from the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
[42 FR 52821, Sept. 30, 1977, as amended at 46 FR 8460, Jan. 27, 1981; 59 FR 14365, Mar. 28, 1994; 68 FR 24879, May 9, 2003; 88 FR 45066, July 14, 2023]
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial information extracted from Kideo
Productions, Inc. and is qualified in its' entirety by reference to such
financial statements.
</LEGEND>
<MULTIPLIER>                                   1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                              JUL-31-1997
<PERIOD-START>                                 AUG-1-1996
<PERIOD-END>                                   JUL-31-1997
<CASH>                                                 164
<SECURITIES>                                             0
<RECEIVABLES>                                           57
<ALLOWANCES>                                           (26)
<INVENTORY>                                            103
<CURRENT-ASSETS>                                       326
<PP&E>                                                 903
<DEPRECIATION>                                         396
<TOTAL-ASSETS>                                       1,488
<CURRENT-LIABILITIES>                                  992
<BONDS>                                                 74
<PREFERRED-MANDATORY>                                    0
<PREFERRED>                                              0
<COMMON>                                                 0
<OTHER-SE>                                             422
<TOTAL-LIABILITY-AND-EQUITY>                         1,488
<SALES>                                              1,346
<TOTAL-REVENUES>                                     1,346
<CGS>                                                1,325
<TOTAL-COSTS>                                        3,860
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                        56
<INTEREST-EXPENSE>                                       0
<INCOME-PRETAX>                                     (3,819)
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                                 (3,819)
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                        (3,819)
<EPS-PRIMARY>                                        (1.37)
<EPS-DILUTED>                                        (1.37)
        


</TABLE>
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1426 Magnesium chloride. ( a ) Magnesium chloride (MgC12·6H2O, CAS Reg. No. 7786-30-3) is a colorless, deliquescent, crystalline material that occurs naturally as the mineral bischofite. It is prepared by dissolving magnesium oxide, hydroxide, or carbonate in aqueous hydrochloric acid solution and crystallizing out magnesium chloride hexahydrate.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 177, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a flavoring agent and adjuvant as defined in § 170.3(o)(12) of this chapter and a nutrient supplement as defined in § 170.3(o)(20) of this chapter.
( 2 ) The ingredient is used in foods at levels not to exceed current good manufacturing practice. The ingredient also may be used in infant formula in accordance with section 412(g) of the Federal Food, Drug, and Cosmetic Act (the act) or with regulations promulgated under section 412(a)(2) of the act.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[50 FR 13559, Apr. 5, 1985; 50 FR 16080, Apr. 24, 1985]